Breast CancerNCT02872363
Does the Wording of Text Message Reminders Improve Uptake in Breast Screening?
A study testing Intervention A - Behavioural Regulation and Intervention B - Priority in people with Breast Cancer and Breast Disease, run by Imperial College Healthcare NHS Trust at 1 site in United Kingdom.
Trial summary
Breast screening is a service offered by the NHS to help detect breast cancer and precancerous changes early at a time when treatment is more likely to be curative. An effective service must reach the 'at risk' but asymptomatic population. Read more about this study
- Who is it for?
- Ages 20 to 100 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer, Breast Disease
- What is being tested?
- Intervention A - Behavioural Regulation and Intervention B - Priority
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7,944 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 9 Aug 2016to 20 Feb 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 100 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women who are eligible and due for breast screening in West London.
Who cannot join
- Women who are not eligible for breast screening due to for example bilateral mastectomies.
- Women who have chosen to not have screening and have informed the screening centre or their GP.
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
Department of Surgery and Cancer, St Mary's Campus, Praed Street, Imperial College London
London, W2 1NY
About this study
Official title: Does the Wording of Text Message Reminders Improve Uptake in Breast Screening? A Randomised Controlled Trial
Breast screening is a service offered by the NHS to help detect breast cancer and precancerous changes early at a time when treatment is more likely to be curative. An effective service must reach the 'at risk' but asymptomatic population. Breast screening uptake in London, consistently falls below the national target and is well below the national average. Uptake in West London is particularly low, with boroughs in Inner North West London having the some of lowest uptake rates in the country.
Routine text message reminders have proven effective at improving uptake of breast screening appointments. However little attention is paid to the content of the messages. Previous studies of text message reminders in other clinical areas have shown that the content of these messages matters and some text messages are more effective than others.
Read more
This protocol describes the design of a randomized controlled trial to investigate the effect of differently worded text messages on the engagement with breast screening in West London.
Two intervention arms were designed taking into consideration results of a 1000 woman survey to highlight the behavioural barriers that most predict attendance. The survey tested 15 behavioural constructs and the two that most strongly predicted history of attendance were used to inform the text message content of the intervention arms for this trial.
To this end, this randomised controlled trial (RCT) will test the current standard practice text message reminder against two intervention text message trial arms informed by the above described survey.
The setting is West of London Breast Screening Service and women aged 47-73 who are due for screening will be randomized to receive one of the three trial arms.
The primary outcome is the difference in uptake between trial arms. Further statistical analysis will analyse the difference in uptake by age group, deprivation score and previous attendance status.
Result will inform how small changes to the word content may have significant effects on attendance at screening mammogram appointments.
Read the detailed description
Background
In the UK breast cancer is the most common female cancer affecting 1 in 8 women, accounting for 31% of all cancers and 15% of cancer deaths in women.1 The NHS breast screening programme (NHSBSP) offers 3-yearly screening to women aged 50-70 years. A pilot of extended screening ages of 47-73 is being trialed in some geographical areas.
In 2015, 75% of women in England attended breast screening. In the same year only 68.3% of women in London and 65.9% in West London respectively had an up-to-day mammogram in the previous 3 years. 2 This falls below both the national average and target uptake of 70%. The success of a screening programme not only relies on the sensitivity of the screening tool and availability of successful treatment but also on reaching the asymptomatic but at risk population.
Recent evidence in breast screening has shown that a simple text message reminder (TMR) is effective. 3,4. One randomized controlled trial showed an increase in attendance by as much as 12%.5 As a result TMRs are being used more frequently by NHS organisations, but with little consideration paid their word content.
Further research testing the word content of TMR to remind patients of routine outpatient hospital appointments has shown that the word choice matters. The most effective message reduced 'did not attend' rates by 3.4 percentage points compared to a control TMR at a London Hospital. 6
Objective
This study aims to test if the word content of TMRs affects the uptake of breast screening.
Trial design
The investigators propose to collaborate with West of London Breast Screening Service (WoLBSS) to test different TMRs through an RCT to increase screening uptake.
The trial will test the effect of differently worded TMRs on the uptake of breast screening in eligible women in West London. This three-armed RCT will test two intervention arms against the current control arm.
Current practice is for women to receive two TMRs at 7 and 4 days prior to their appointment. Therefore the current message will be maintained as the control message for both TMR 1 (7 days prior to appointment) and TMR 2 (4 days prior to appointment). The intervention arms will contain the intervention TMRs and will be sent out as both TMR1 and TMR2. During the trial period women due for screening will be randomized to receive one of the three trial arms (control, intervention arm 1 or intervention arm 2. The TMRs will be sent out 7 days and 4 days before the breast screening appointment during the trial period as they are currently sent out as part of routine practice. Women will receive the same message on the 7th day and the 4th day before their appointment. WoLBSS will inform the research team of a woman's attendance status at the end of the screening rounds.
Methods:
Study setting
This study will be run in West London in collaboration with WoLBSS, which currently provides the routine TMR service based on data from a previous trial.5 The research team will work closely with the WoLBSS team to run the RCT through the existing infrastructure used to send out current messages.
Eligibility Criteria
Inclusion Criteria
Women who are eligible and due for breast screening in West London.
Exclusion Criteria
Women who are not eligible for breast screening due to for example bilateral mastectomies.
Women who have chosen to not have screening and have informed the screening centre or their GP.
Withdrawal Criteria
Any woman who chooses to not take part in screening or to receive a TMR and has informed the screening centre or their GP.
Interventions
The RCT will have three arms.
- control (current TMR)
- Intervention 1 - Behavioural regulation TMR
- Intervention 2 - Priority TMR
The choice of the content of the intervention text messages has been based on a survey of 1000 women run by the research team that evaluated how 15 behavioural constructs predicted the outcome measures of women's history of attendance and their intention to attend. Two strong constructs that predict both history of attendance and intention to attend were 'behavioural regulation' i.e. making a plan/note in a diary to attend breast screening and 'priority' i.e. how much a woman feels that screening is a priority.
Therefore the word content of two TMRs was constructed to take these into account.
Both intervention TMRs have been reviewed and approved by the WoLBSS routine care team as well as the clinical lead for screening and a Public Health Consultant in Cancer screening at NHS England.
Control - (current TMR)
'Don't forget your breast screening appointment at (time) (date) at (Site). Please call 02033136644 to rearrange or cancel'
Intervention arm 1 - Behavioural Regulation
'Don't forget to make a diary note of your screening mammogram appt at (time) (date) at (site). Call 02033136644 to rearrange.'
Intervention arm 2 - Priority
'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'
Outcomes
The primary end point is the rate of uptake of screening at the end of the screening round. Trial arms will be powered and sample size collected to detect a 3% uptake in screening. The trial will close when the sample size is reached.
The secondary outcomes are uptake according to age, deprivation score and previous history of attendance.
Participant Timeline
Women will be routinely invited for their screening mammogram as per standard procedure approximately three weeks before their appointment. The research team will then randomise an anonymized list of women to receive one of the three TMRs. The TMR will then be sent at the same times as the current standard TMRs are sent out 7 and 4 days prior to the appointment.
Sample Size
The sample size was calculated to detect a 3% difference in uptake between groups with a 5% margin for type I and 20% margin for type II error. This expected improvement in uptake is deemed to be both realistic and operationally significant to the service. The uptake in West London in 2015 was 65.9%. The investigators therefore calculated a minimum sample size for each trial arm to be 3,832 with a total sample size of 11,496.
Recruitment
For each screening round WoLBSS will invite women for breast screening as per usual. It is not possible to identify at the time of randomization which women have provided WoLBSS with their phone number. For this reason all women due for screening will be randomised. However, only women who have given their mobile phone number will be able to receive a TMR.
Randomisation
Each screening round a list of women will be forward to iPlato Patient Care Messaging with their allocated appointment date, time and location. The participant list will then be randomised by iPlato into trial arms and allocated to receive one of the three TMRs using the Mersenne Twister algorithm.
Once randomised the list of women due for screening will be uploaded to the iPlato platform. The iPlato system will link each patients NHS number to WoLBSS record and retrieve a mobile phone number where one is available.
WoLBSS uses iPlato Patient Care Messaging currently to send out the existing text message reminder. iPlato is a communication platform developed specifically for health services and can send reminder messages on behalf of GPs and hospitals.
Data collection and management
Data will be collected by the WoLBSS IT system including the primary research outcome of attendance status. iPlato will collect data on accuracy of phone numbers and messages delivery status. Anonymised data will be retrieved and passed onto the research team. The data will be handled on NHS N3 computers with password protection, the research team's personal laptops with secure password protection and Imperial College London's secure virtual private network. Any transmission of data via email will be within secure NHS.net and NHS trust email accounts between WoLBSS and the research team and within the secure Imperial College email accounts and the virtual private network amongst the research team.
Data collected will include the age, year of birth, first 3-4 digits of the postcode, ethnicity, previous attendance history and availability of a mobile phone number.
It is possible that participants are subject to other trials however due to the nature of the trial it is not appropriate to contact patients to find out. It is not necessary in terms of impact on the results.
Consent
The premise of the study is whether a subtle change in a text message can increase the number of patients attending their breast screening appointment. A pre-warning that patients may receive TMR that may be modified would undermine the premise of the study and affect results. This is because of participation bias, which would indicate that subjects who know they are participating in a trial are more likely to try and do what they think the researcher wants them to do. Taking explicit consent would therefore also undermine the study design.
Only women who have given them mobile phone number to WoLBSS directly, will be able to receive a TMR prior to their appointment. Therefore they have in the past given explicit consent to receive a TMR by the service. No woman who has not previously given her mobile number to the service will receive a TMR.
- Conditions
- Breast Cancer, Breast Disease
- Being tested
- Intervention A - Behavioural Regulation, Intervention B - Priority
- Keywords
- breast screening, breast cancer, mammogram, uptake, reminder, text message, SMS
- Medical subject headings
- Breast Neoplasms, Breast Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention A - Behavioural RegulationOther
SMS reminder with 'Behavioural Regulation' message:
'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'
Intervention B - PriorityOther
SMS reminder with 'Priority' message:
'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment. |
| Intervention A - Behavioural Regulation | Experimental | Intervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment. Receives: Other: Intervention A - Behavioural Regulation |
| Intervention B - Priority | Experimental | Intervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment. Receives: Other: Intervention B - Priority |
What is being measured
The primary outcome is the main question the study is designed to answer.
Uptake of the timed appointment provided by the screening service
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
Measured: Usually within a month (Individual timed appointment is provided by the screening service)
Secondary outcomes (4)
Uptake of time appointment by age group
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
Measured: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by number of previous invitations received
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
Measured: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by history of attendance
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
Measured: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by deprivation score
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
Measured: Usually within a month (Individual timed appointment is provided by the screening service)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Aug 2016 (estimated)
- Study start9 Aug 2016
- Primary completion8 Nov 2016
- Study completion20 Feb 2017
Why it stopped: The screening service moved to a pan-London service and the trial was not able to be continued.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 7,944 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College Healthcare NHS Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Imperial College London
- Responsible party
- Sponsor
- Investigators
- Sarah W Huf, MBBS BSc, Principal investigator, Imperial College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02872363
- Sponsor's protocol ID
- 16/YH/0276
- Status last verified
- Apr 2019
- First submitted
- 19 Jul 2016
- Last updated
- 11 Apr 2019
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No: There is no intention to make individual participant data available. Data will be analysed at aggregate level.
Publications
Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
PubMed 32779730
Study at a glance
From the registry record, last updated by the sponsor on 11 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does the Wording of Text Message Reminders Improve Uptake in Breast Screening? A Randomised Controlled Trial
- ClinicalTrials.gov ID
- NCT02872363
- Acronym / sponsor ID
- 16/YH/0276
- Conditions
- Breast Cancer, Breast Disease
- Keywords
- breast screening, breast cancer, mammogram, uptake, reminder, text message, SMS
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The screening service moved to a pan-London service and the trial was not able to be continued.
- Enrolment
- 7,944 participants (actual)
- Lead sponsor
- Imperial College Healthcare NHS TrustUniversity, hospital or other
- Collaborators
- Imperial College London
- Study start
- 9 Aug 2016 (actual)
- Primary completion
- 8 Nov 2016 (actual)
- Study completion
- 20 Feb 2017 (actual)
- First posted
- 19 Aug 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Breast screening is a service offered by the NHS to help detect breast cancer and precancerous changes early at a time when treatment is more likely to be curative. An effective service must reach the 'at risk' but asymptomatic population. Breast screening uptake in London, consistently falls below the national target and is well below the national average. Uptake in West London is particularly low, with boroughs in Inner North West London having the some of lowest uptake rates in the country.
Routine text message reminders have proven effective at improving uptake of breast screening appointments. However little attention is paid to the content of the messages. Previous studies of text message reminders in other clinical areas have shown that the content of these messages matters and some text messages are more effective than others.
This protocol describes the design of a randomized controlled trial to investigate the effect of differently worded text messages on the engagement with breast screening in West London.
Two intervention arms were designed taking into consideration results of a 1000 woman survey to highlight the behavioural barriers that most predict attendance. The survey tested 15 behavioural constructs and the two that most strongly predicted history of attendance were used to inform the text message content of the intervention arms for this trial.
To this end, this randomised controlled trial (RCT) will test the current standard practice text message reminder against two intervention text message trial arms informed by the above described survey.
The setting is West of London Breast Screening Service and women aged 47-73 who are due for screening will be randomized to receive one of the three trial arms.
The primary outcome is the difference in uptake between trial arms. Further statistical analysis will analyse the difference in uptake by age group, deprivation score and previous attendance status.
Result will inform how small changes to the word content may have significant effects on attendance at screening mammogram appointments.
Detailed description
Background
In the UK breast cancer is the most common female cancer affecting 1 in 8 women, accounting for 31% of all cancers and 15% of cancer deaths in women.1 The NHS breast screening programme (NHSBSP) offers 3-yearly screening to women aged 50-70 years. A pilot of extended screening ages of 47-73 is being trialed in some geographical areas.
In 2015, 75% of women in England attended breast screening. In the same year only 68.3% of women in London and 65.9% in West London respectively had an up-to-day mammogram in the previous 3 years. 2 This falls below both the national average and target uptake of 70%. The success of a screening programme not only relies on the sensitivity of the screening tool and availability of successful treatment but also on reaching the asymptomatic but at risk population.
Recent evidence in breast screening has shown that a simple text message reminder (TMR) is effective. 3,4. One randomized controlled trial showed an increase in attendance by as much as 12%.5 As a result TMRs are being used more frequently by NHS organisations, but with little consideration paid their word content.
Further research testing the word content of TMR to remind patients of routine outpatient hospital appointments has shown that the word choice matters. The most effective message reduced 'did not attend' rates by 3.4 percentage points compared to a control TMR at a London Hospital. 6
Objective
This study aims to test if the word content of TMRs affects the uptake of breast screening.
Trial design
The investigators propose to collaborate with West of London Breast Screening Service (WoLBSS) to test different TMRs through an RCT to increase screening uptake.
The trial will test the effect of differently worded TMRs on the uptake of breast screening in eligible women in West London. This three-armed RCT will test two intervention arms against the current control arm.
Current practice is for women to receive two TMRs at 7 and 4 days prior to their appointment. Therefore the current message will be maintained as the control message for both TMR 1 (7 days prior to appointment) and TMR 2 (4 days prior to appointment). The intervention arms will contain the intervention TMRs and will be sent out as both TMR1 and TMR2. During the trial period women due for screening will be randomized to receive one of the three trial arms (control, intervention arm 1 or intervention arm 2. The TMRs will be sent out 7 days and 4 days before the breast screening appointment during the trial period as they are currently sent out as part of routine practice. Women will receive the same message on the 7th day and the 4th day before their appointment. WoLBSS will inform the research team of a woman's attendance status at the end of the screening rounds.
Methods:
Study setting
This study will be run in West London in collaboration with WoLBSS, which currently provides the routine TMR service based on data from a previous trial.5 The research team will work closely with the WoLBSS team to run the RCT through the existing infrastructure used to send out current messages.
Eligibility Criteria
Inclusion Criteria
Women who are eligible and due for breast screening in West London.
Exclusion Criteria
Women who are not eligible for breast screening due to for example bilateral mastectomies.
Women who have chosen to not have screening and have informed the screening centre or their GP.
Withdrawal Criteria
Any woman who chooses to not take part in screening or to receive a TMR and has informed the screening centre or their GP.
Interventions
The RCT will have three arms.
- control (current TMR)
- Intervention 1 - Behavioural regulation TMR
- Intervention 2 - Priority TMR
The choice of the content of the intervention text messages has been based on a survey of 1000 women run by the research team that evaluated how 15 behavioural constructs predicted the outcome measures of women's history of attendance and their intention to attend. Two strong constructs that predict both history of attendance and intention to attend were 'behavioural regulation' i.e. making a plan/note in a diary to attend breast screening and 'priority' i.e. how much a woman feels that screening is a priority.
Therefore the word content of two TMRs was constructed to take these into account.
Both intervention TMRs have been reviewed and approved by the WoLBSS routine care team as well as the clinical lead for screening and a Public Health Consultant in Cancer screening at NHS England.
Control - (current TMR)
'Don't forget your breast screening appointment at (time) (date) at (Site). Please call 02033136644 to rearrange or cancel'
Intervention arm 1 - Behavioural Regulation
'Don't forget to make a diary note of your screening mammogram appt at (time) (date) at (site). Call 02033136644 to rearrange.'
Intervention arm 2 - Priority
'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'
Outcomes
The primary end point is the rate of uptake of screening at the end of the screening round. Trial arms will be powered and sample size collected to detect a 3% uptake in screening. The trial will close when the sample size is reached.
The secondary outcomes are uptake according to age, deprivation score and previous history of attendance.
Participant Timeline
Women will be routinely invited for their screening mammogram as per standard procedure approximately three weeks before their appointment. The research team will then randomise an anonymized list of women to receive one of the three TMRs. The TMR will then be sent at the same times as the current standard TMRs are sent out 7 and 4 days prior to the appointment.
Sample Size
The sample size was calculated to detect a 3% difference in uptake between groups with a 5% margin for type I and 20% margin for type II error. This expected improvement in uptake is deemed to be both realistic and operationally significant to the service. The uptake in West London in 2015 was 65.9%. The investigators therefore calculated a minimum sample size for each trial arm to be 3,832 with a total sample size of 11,496.
Recruitment
For each screening round WoLBSS will invite women for breast screening as per usual. It is not possible to identify at the time of randomization which women have provided WoLBSS with their phone number. For this reason all women due for screening will be randomised. However, only women who have given their mobile phone number will be able to receive a TMR.
Randomisation
Each screening round a list of women will be forward to iPlato Patient Care Messaging with their allocated appointment date, time and location. The participant list will then be randomised by iPlato into trial arms and allocated to receive one of the three TMRs using the Mersenne Twister algorithm.
Once randomised the list of women due for screening will be uploaded to the iPlato platform. The iPlato system will link each patients NHS number to WoLBSS record and retrieve a mobile phone number where one is available.
WoLBSS uses iPlato Patient Care Messaging currently to send out the existing text message reminder. iPlato is a communication platform developed specifically for health services and can send reminder messages on behalf of GPs and hospitals.
Data collection and management
Data will be collected by the WoLBSS IT system including the primary research outcome of attendance status. iPlato will collect data on accuracy of phone numbers and messages delivery status. Anonymised data will be retrieved and passed onto the research team. The data will be handled on NHS N3 computers with password protection, the research team's personal laptops with secure password protection and Imperial College London's secure virtual private network. Any transmission of data via email will be within secure NHS.net and NHS trust email accounts between WoLBSS and the research team and within the secure Imperial College email accounts and the virtual private network amongst the research team.
Data collected will include the age, year of birth, first 3-4 digits of the postcode, ethnicity, previous attendance history and availability of a mobile phone number.
It is possible that participants are subject to other trials however due to the nature of the trial it is not appropriate to contact patients to find out. It is not necessary in terms of impact on the results.
Consent
The premise of the study is whether a subtle change in a text message can increase the number of patients attending their breast screening appointment. A pre-warning that patients may receive TMR that may be modified would undermine the premise of the study and affect results. This is because of participation bias, which would indicate that subjects who know they are participating in a trial are more likely to try and do what they think the researcher wants them to do. Taking explicit consent would therefore also undermine the study design.
Only women who have given them mobile phone number to WoLBSS directly, will be able to receive a TMR prior to their appointment. Therefore they have in the past given explicit consent to receive a TMR by the service. No woman who has not previously given her mobile number to the service will receive a TMR.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –The current standard care text message reminder (SMS) that women routinely receive when being invited for their breast screening mammogram will be sent to the control group at 7 and 4 days before their timed appointment. |
| Intervention A - Behavioural Regulation | Experimental | Other: Intervention A - Behavioural RegulationIntervention A will be a text message reminder (SMS) containing a behavioural regulation message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment. |
| Intervention B - Priority | Experimental | Other: Intervention B - PriorityIntervention B will be a text message reminder (SMS) containing a priority message. Women will be sent this SMS at 7 and 4 days prior to their timed appointment. |
Who may qualify
- Ages
- 20 to 100 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Women who are eligible and due for breast screening in West London.
Key exclusion criteria (2 listed)
- Women who are not eligible for breast screening due to for example bilateral mastectomies.
- Women who have chosen to not have screening and have informed the screening centre or their GP.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intervention A - Behavioural RegulationSMS reminder with 'Behavioural Regulation' message: 'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange' | Other | Intervention A - Behavioural Regulation |
| Intervention B - PrioritySMS reminder with 'Priority' message: 'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.' | Other | Intervention B - Priority |
Primary outcome
Uptake of the timed appointment provided by the screening service
Time frame: Usually within a month (Individual timed appointment is provided by the screening service)
Each patient is invited to an individual timed appointment. The outcome measure will be assessed based on if women attend their timed appointment. Usually this is within a month of the invitation letter being sent.
4 secondary outcomes
Uptake of time appointment by age group
Time frame: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by number of previous invitations received
Time frame: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by history of attendance
Time frame: Usually within a month (Individual timed appointment is provided by the screening service)
Uptake of timed appointment by deprivation score
Time frame: Usually within a month (Individual timed appointment is provided by the screening service)
Results and safety
The study was stopped early (reason given: The screening service moved to a pan-London service and the trial was not able to be continued.). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Apr 2019.
- Derived from this study: PubMed 32779730Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
- Individual participant dataSharing planned: No. There is no intention to make individual participant data available. Data will be analysed at aggregate level.
Related trials for Breast Cancer
Active, not recruiting
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
No Evidence of Disease, BRCA1 Syndrome
Active, not recruitingPhase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Active, not recruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
RecruitingPhase 1/2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Pancreatic Cancer, Renal Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sarah W Huf, MBBS BSc principal investigator
Imperial College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention A - Behavioural Regulation and Intervention B - Priority in people with Breast Cancer and Breast Disease, run by Imperial College Healthcare NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 11 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: The screening service moved to a pan-London service and the trial was not able to be continued.). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Uptake of the timed appointment provided by the screening service (time frame: Usually within a month (Individual timed appointment is provided by the screening service)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02872363, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Apr 2019; AzTrials last refreshed its copy on 26 Oct 2026.